Alexandria Venture Investments

Hoofprint Biome is a biotechnology company that develops probiotics and natural enzymes to enhance the sustainability of ruminant livestock production. Their products improve cattle health and digestive care by reducing methane emissions, thereby enabling the livestock industry to adopt more sustainable practices through microbiome engineering.

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating disease-driving cells. Utilizing its unique cytotoxicity-targeting chimera platform, the company focuses on creating oncology therapeutics that address not only cancer but also inflammatory and autoimmune diseases. By targeting and eliminating these harmful cells, Solu Therapeutics seeks to enhance treatment efficacy and reduce the associated risks in oncology, ultimately aiming to improve patient outcomes in various medical conditions.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.

Jupiter Bioventures is a venture builder company dedicated to de-risking early-stage therapeutic projects. It operates by evaluating opportunities through a specific set of investment criteria and providing initial seed capital to founders. This approach enables the growth of innovative projects in the biotechnology sector, supporting entrepreneurs as they navigate the challenges of early development. By focusing on early-stage initiatives, Jupiter Bioventures aims to foster advancements in therapeutic solutions while minimizing the inherent risks associated with new ventures.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics aimed at addressing significant and unmet needs in central nervous system disorders. By leveraging precision medicine, Leal Therapeutics seeks to provide effective treatment options for patients suffering from various neurological conditions. The company's commitment to advancing therapeutic solutions is reflected in its dedication to improving patient outcomes through targeted interventions.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.

Judo Bio is a biotechnology company focused on developing precision therapeutics that target specific cell populations to treat genetic diseases. Utilizing an innovative receptor targeting approach, Judo Bio is building a pipeline of treatments designed to address both common and rare diseases. Currently, the company is operating in stealth mode, indicating a period of research and development prior to a public launch or disclosure of its initiatives.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the obstacles posed by tumors. Through its innovative approach, OverT Bio aims to enhance the effectiveness and durability of immunotherapies, contributing to advancements in cancer identification and treatment within the healthcare sector.

Enlaza Therapeutics is a biotechnology research company founded in 2020 and headquartered in La Jolla, California. The company focuses on developing novel protein therapeutics aimed at providing more effective and safer treatment options for patients. Utilizing advanced synthetic biology technology, Enlaza Therapeutics specializes in site-specific covalent coupling driven by drug binding. This innovative approach allows the development of first-in-class covalent biologics that have the potential to deliver enhanced efficacy and improved safety profiles compared to traditional therapies.

Clasp Therapeutics is a biotechnology company focused on developing innovative cancer immunotherapeutics. The company has created a platform that aims to enhance the ability of the immune system to recognize and eliminate challenging tumors associated with common driver mutations, irrespective of tumor type. By leveraging precision medicine, Clasp Therapeutics seeks to identify cancer-specific markers that allow for the targeted destruction of tumor cells, thereby improving treatment outcomes for patients with difficult-to-treat cancers.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Ability Biologics is a biotechnology company focused on developing innovative immune-modulating biotherapeutics aimed at addressing significant unmet medical needs in patients suffering from cancer and autoimmune diseases. The company leverages a platform that employs advanced artificial intelligence to analyze a vast database of antigen-antibody interactions. This technology enables the creation of tailored and effective antibody therapeutics designed to provide healthcare professionals with potent treatment options for conditions that currently lack adequate solutions. Through its commitment to addressing these critical health challenges, Ability Biologics seeks to enhance patient outcomes and advance the field of immunotherapy.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Georgiamune is a biotechnology company specializing in immunotherapy for cancer treatment. It develops advanced immunotherapeutic and homeostatic therapies aimed at enhancing the body's natural defenses against cancer, with the goal of improving patient recovery times.

Solu Therapeutics is a precision medicine company dedicated to developing innovative therapeutics aimed at eliminating disease-driving cells. Utilizing its unique cytotoxicity-targeting chimera platform, the company focuses on creating oncology therapeutics that address not only cancer but also inflammatory and autoimmune diseases. By targeting and eliminating these harmful cells, Solu Therapeutics seeks to enhance treatment efficacy and reduce the associated risks in oncology, ultimately aiming to improve patient outcomes in various medical conditions.

Bitterroot Bio is a biotechnology company focused on developing innovative therapies for cardiovascular disease by harnessing the immune system's natural capabilities. The company conducts research to uncover the essential roles of immune cells and immune modulators in the onset and progression of cardiovascular conditions. By leveraging immunotherapy, Bitterroot Bio aims to create and deliver novel medicines that can significantly improve treatment options for patients suffering from these diseases, thereby transforming the landscape of cardiovascular care.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Tiamat Sciences is a start-up focused on producing affordable, animal-free growth factors and biomolecules through innovative plant-based bioreactors. Utilizing proprietary technology, the company manufactures a diverse array of high-value proteins, including antigens and growth factors, achieving significant cost reductions—up to 10 times lower than traditional methods, with potential for further reductions at scale. This technology not only enhances production efficiency but also supports ecological sustainability by providing plant-based alternatives to animal-derived materials in the pharmaceutical industry. Tiamat's approach increases the safety and speed of production, positioning it as a strategic partner for scaling operations in burgeoning sectors such as cellular agriculture and gene therapy. The low capital investment required for facility setup makes Tiamat an attractive option in a market poised for substantial growth.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By investigating the unique characteristics of the bat genome, the company aims to identify and develop therapeutics for various diseases. Leveraging insights gained from bat biology, Paratus Sciences seeks to enable patients to combat and potentially cure the diseases they face. Through its innovative approach, the company aspires to contribute significantly to advancements in medical treatments and public health.

Melonfrost is a biotechnology company located in Brooklyn, New York. It specializes in developing a clinical research platform aimed at optimizing biological strains by addressing operational bottlenecks. The company employs a combination of machine learning, proprietary artificial intelligence, and advanced hardware to facilitate real-time cell evolution. This innovative approach enables Melonfrost to explore the biological landscape effectively and implement advancements in robotics, sensing, fluidics, and environmental control. By streamlining scientific labor processes, Melonfrost significantly reduces the time required to bring bioproducts to market, thereby enhancing the efficiency and effectiveness of biotechnological innovations.

Dantari is a biotechnology company focused on developing innovative treatments for serious diseases, including cancer and disorders of the central nervous system. The company has created a pharmaceutical platform that facilitates the research and development of both small and large molecule therapeutics capable of crossing the blood-brain barrier. This advancement allows for the rapid progression of therapies aimed at delivering meaningful medical improvements to patients' lives. Additionally, Dantari's novel antibody-drug conjugate platform features a higher drug-to-antibody ratio compared to traditional approaches, along with the ability to release therapeutic payloads in a tunable manner. This technology enhances the efficacy and therapeutic potential of its medicines, ultimately aiming to improve patient health outcomes.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. It employs a combination of human genetics, functional genomics, and advanced microscopy techniques to identify novel targets and therapeutics. The company utilizes viral tools and platforms for screening targets that influence the progression of neurodegenerative conditions, alongside functional genetic screening and multi-omics methods. By integrating these state-of-the-art approaches, Cajal Neuroscience aims to advance precision medicine, ultimately enabling healthcare professionals to improve treatment outcomes for patients suffering from neurodegenerative disorders.

Haystack Oncology is an oncology company that specializes in advanced liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. The company utilizes state-of-the-art circulating tumor DNA detection methods to enhance the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. By analyzing tumor-specific markers in blood samples, Haystack Oncology's technology provides high sensitivity for early detection of recurrent disease, thereby enabling healthcare teams to effectively manage cancer treatment. The company's innovative approach seeks to transform how cancer is monitored and treated, ultimately benefiting patients through improved diagnostic accuracy and treatment effectiveness.

Tavros Therapeutics is a biotechnology company based in Durham, North Carolina, focused on discovering and developing therapies for cancer. Founded in 2019, the company aims to advance oncology treatments by identifying vulnerabilities within tumors. This approach allows for targeted drug combinations, potentially improving outcomes for patients with oncological diseases.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Cartography Biosciences is a biotechnology company focused on developing cancer therapies through precision medicine. The company aims to revolutionize cancer immunotherapies by identifying the safest and most effective targets for treatment. Utilizing a platform-based cell therapy approach, Cartography employs single-cell analysis to discover novel CAR-T targets. This methodology empowers clients to enhance their molecular biology and computational methods, facilitating the advancement of innovative cancer immunotherapies. By prioritizing precision and safety, Cartography Biosciences is dedicated to transforming the landscape of cancer treatment.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Eclipse BioInnovations is a prominent RNA genomics company established in 2017, leveraging innovative technology developed at the University of California, San Diego. The company specializes in advanced RNA genomics platforms aimed at enhancing RNA medicines and scientific research. Its founders introduced eCLIP, a highly efficient CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse BioInnovations offers a comprehensive suite of RNA genomics technologies, including eCLIP-RBP for mapping RNA binding proteins, miR-eCLIP for analyzing the miR-interactome, m6A-eCLIP for studying RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for streamlining CRISPR library preparation. These products are available as services and kits for biopharmaceutical companies and academic researchers and can be customized to meet specific client needs. By providing these specialized genomics-based products and services, Eclipse BioInnovations empowers scientists to accelerate their research and develop effective therapies for various human diseases.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.

NextVivo is a biotech company focused on advancing drug development through its innovative immune organoid technology platform. The company aims to create safer and more effective therapies by utilizing immune-competent, human-derived models. Its technology involves the use of miniature 3D cell cultures, known as organoids, which accurately replicate the composition, structure, and function of human tissue. This unique approach allows for the modeling of both humoral and cellular immune responses outside the human body. By enabling the testing of pre-clinical candidates on ex vivo human tissue models, NextVivo facilitates the identification of the most promising therapies for clinical development, thereby enhancing the drug discovery process.

Fountain Therapeutics, established in 2018 and headquartered in San Francisco, specializes in developing treatments for age-related diseases using cellular models and an AI-based platform for target discovery. The company aims to recreate aging's complex hallmarks in lab dishes, combining this model with artificial intelligence and computer vision to identify novel targets unbiasedly.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company creates therapies with disease-specific applications that enhance patient outcomes by optimizing pharmacokinetics and pharmacodynamics through the targeted delivery of dual and complementary cytokines to affected tissues or cells. This innovative approach seeks to provide patients with curative treatment options for various conditions, including cancer, autoimmune disorders, and infectious diseases.

Mozart Therapeutics is a biotechnology startup dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company specializes in creating disease-modifying CD8 T cell modulators, leveraging a unique regulatory CD8 T cell network to target a specific subset of T lymphocytes. These modulators aim to restore immune balance and mitigate the damage caused by autoreactive and pathogenic immune responses. By focusing on first-in-class CD8 Treg modulators, Mozart Therapeutics seeks to delay the onset and improve the management of various autoimmune disorders, thereby providing healthcare professionals with advanced treatment options for their patients.

BIOMILQ is a women-owned start-up based in Durham, North Carolina, founded in 2020. The company specializes in producing nutritionally equivalent breastmilk using cultured human mammary cells. By leveraging a unique biomanufacturing platform, BIOMILQ aims to create bioauthentic human milk ingredients that support early-life nutrition. Its products are designed to provide a sustainable and nutritious alternative for mothers and caregivers, promoting immune, gut, and neurological development in infants. Through its patented technology, BIOMILQ seeks to empower families with options that mirror the benefits of natural breastmilk, enhancing infant health and nutrition.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focusing on the creation and commercialization of human tissue-based products for regenerative medicine and vascular surgery. Established in 2004, the company specializes in developing acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to prevent rejection. These engineered tissues are designed for use as vascular grafts, providing solutions for patients requiring vascular repair or replacement. Humacyte aims to deliver universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while advancing the field of medicine.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Thryv Therapeutics is a precision medicine company focused on developing innovative therapeutics for Long QT Syndrome and other arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, as well as atrial fibrillation and treatment-resistant cancers. Thryv Therapeutics specializes in creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to provide therapies that can significantly reduce the risk of sudden cardiac death and enhance the quality of life for patients affected by these serious conditions.

Deep Genomics Inc. is an artificial intelligence therapeutics company based in Toronto, Canada, founded in 2014. The company focuses on developing individualized genetic medicines by utilizing AI systems to enhance various aspects of drug discovery and development, such as target discovery, lead optimization, toxicity assessment, and innovative trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic underpinnings of diseases at the RNA and DNA levels, targeting rare metabolic, ophthalmologic, and neurodegenerative disorders. Its AI-powered platform decodes the complexities of RNA biology, enabling the identification of novel therapeutic targets and mechanisms that traditional methods cannot access. This innovative approach positions Deep Genomics at the forefront of revolutionizing drug discovery, ultimately aiming to provide new treatments for currently untreatable diseases.

Wugen is a biotechnology company focused on developing innovative off-the-shelf cellular therapies for cancer treatment. The company specializes in natural killer (NK) cell and CAR-T immuno-oncology therapies, utilizing healthy donor cells that are manipulated to enhance their ability to target and eliminate cancer cells. Wugen's proprietary Moneta platform, along with its expertise in genomic engineering, allows for the creation of a new class of memory NK cell therapies aimed at addressing solid tumors, acute myeloid leukemia, and T-cell malignancies. Through its advancements, Wugen seeks to provide effective treatment options for patients facing life-threatening tumors.

ImmuneID is a precision immunology company that specializes in identifying and therapeutically targeting antibody interactions responsible for immune diseases. Utilizing a proprietary platform, it employs massively parallel, multiplexed, and unbiased systems to analyze millions of these interactions. This innovative approach allows researchers to observe human immune responses throughout the progression of various diseases, including autoimmunity, severe allergies, oncology, and infectious diseases. By focusing on the intricate dynamics of the immune system, ImmuneID aims to develop more effective therapeutics that can improve patient outcomes in these challenging areas of health.

Neurona Therapeutics Inc. is a pre-clinical biotechnology company based in South San Francisco, California, focused on developing cell-based therapies for neurological disorders. Founded by a team of neuroscientists and stem cell experts from the University of California, San Francisco, Neurona aims to create therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. The company is dedicated to addressing chronic neurological diseases through regenerative neural cell therapies, which hold the potential for single-dose curative treatments. Drawing on nearly two decades of research, Neurona believes that certain subpopulations of neurons can effectively integrate and repair dysfunctional neural circuits, thus offering new hope for patients facing significant unmet medical needs.

Mnemo Therapeutics is a biotechnology company focused on developing immune-based therapies, particularly cell therapies, aimed at providing accessible cures for solid tumors and blood cancers. The company's EnfiniT platform serves as an advanced drug discovery engine that harnesses a specific class of antigens along with various technologies to target tumorous epitopes found across multiple cancer types. By utilizing epigenetic variation and precision genetic engineering technologies, Mnemo Therapeutics creates allogeneic treatments designed to effectively address and overcome these diseases, advancing the field of cancer treatment.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

miRecule, Inc. is a biotechnology company focused on developing innovative therapies for cancer and muscular dystrophy through its proprietary microRNA-based drug discovery platform, DREAmiR. Founded in 2016 and based in Gaithersburg, Maryland, the company leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. This platform integrates genomic sequencing, expression, and prognostic data to identify candidates for microRNA replacement therapy, enabling the creation of tailored RNA therapeutics that can directly target and rectify these genetic issues. miRecule's research is aimed at developing first-in-class therapies, with current lead programs addressing Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy. Through its advanced approach, miRecule aims to provide solutions that help patients overcome the debilitating effects of their conditions.

Soteria Biotherapeutics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company focuses on developing innovative immunotherapies, specifically next-generation conditionally active bispecific T-cell engaging antibodies aimed at treating patients with solid tumors. Utilizing its proprietary T-LITE™ platform, Soteria creates bispecific antibody therapies that are activated by small molecules, allowing for safer and more effective treatments. This technology facilitates pulsatile activity, which reduces side effects and enables higher dosing, ultimately enhancing the therapeutic potential for cancer patients.

TwinStrand Biosciences, established in 2015 and based in Bellevue, Washington, specializes in advancing DNA sequencing technology. The company's core innovation, Duplex Sequencing, enhances sequencing accuracy by over 10,000 times, enabling the detection of previously invisible mutations. This breakthrough technology has wide-ranging applications, including oncology, infectious disease diagnosis, organ transplant monitoring, genetic health, and forensics.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, aimed at creating DNA-based products across various industries. Founded in 2013, the company has developed a proprietary method that allows for the reliable, affordable, and sustainable production of long, high-quality, sequence-specific DNA. This innovative technology is designed to support advancements in industrial synthetic biology, personalized therapeutics, precision diagnostics, and has potential applications in information storage and nanotechnology. With a strong executive and scientific team, as well as a robust intellectual property portfolio, Molecular Assemblies is positioned to enhance the capabilities of researchers and contribute to the evolution of DNA-based applications.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Vera Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2016 and formerly known as Trucode Gene Repair, Inc. The company focuses on developing innovative biologic therapeutics with the potential to transform treatment for patients suffering from serious immunological diseases and genetic disorders. Its lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once weekly, designed to inhibit factors that stimulate the production of autoantibodies associated with autoimmune diseases. Additionally, Vera Therapeutics is utilizing gene-editing technology aimed at addressing conditions such as sickle cell disease and cystic fibrosis, striving to enhance gene detection and regulation for improved patient outcomes.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

Encodia, Inc. is a biotechnology company based in San Diego, California, founded in 2015. The company specializes in proteomics research, providing innovative solutions for protein analysis through its proprietary technology. Encodia's platform utilizes a novel reverse-translation process that converts peptide sequence information into a DNA library, facilitating scalable and efficient protein sequencing. This technology allows researchers to gain comprehensive insights into cellular processes, thereby advancing personalized medicine and accelerating the discovery of novel approaches to address complex diseases. By democratizing protein sequencing, Encodia aims to enhance the capabilities of scientists in their pursuit of understanding the proteome.

Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Faze Medicines is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. It focuses on developing small molecule drugs targeting key drivers of disease pathology, with initial therapeutic areas including amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). The company employs advanced screening and proteomics techniques to define condensate interaction networks, aiming to pioneer innovative therapeutics based on biomolecular condensates. Through its research, Faze Medicines seeks to provide effective treatments for complex diseases such as ALS and frontotemporal dementia (FTD).

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed to treat acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, thereby allowing for selective targeting of cancer cells while sparing normal cells. This innovative approach aims to minimize the toxicities associated with traditional immunotherapies, such as bispecific antibodies and CAR T cells, which often affect both cancerous and healthy cells. Vor Biopharma's mission is to provide safer and more effective treatment options for patients with hematological malignancies by creating therapies that protect healthy, functional cells from depletion during targeted cancer treatments.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

TARA Biosystems, Inc. is a biotechnology company that specializes in developing organ-on-a-chip technology for evaluating new therapies and drug compounds, particularly in the field of cardiac medicine. Founded in 2014 and based in the United States, the company produces predictive in vitro human cardiac tissue models derived from human stem cells. These models are matured to physiologically relevant adult-like levels, allowing for accurate measurement of cardiac functionality, including contractile force. TARA Biosystems focuses on enhancing drug discovery and safety assessment processes by providing high-fidelity solutions that enable faster and safer development of new medicines. By harnessing human biology and data, the company aims to transform cardiac drug discovery and improve patient health outcomes.

MoMa Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company specializes in discovering precision medicines by targeting the molecular machines that are fundamental to human disease. Formerly known as ATPases NewCo, Inc., MoMa Therapeutics utilizes a unique platform that leverages the shared characteristics of ATPase enzymes, including their large-scale conformational changes and energy-driven mechanics. By integrating advances in structural biology and small-molecule drug discovery, MoMa Therapeutics aims to develop therapies targeting this previously challenging class of enzymes, thereby advancing the field of precision medicine.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

TwinStrand Biosciences, established in 2015 and based in Bellevue, Washington, specializes in advancing DNA sequencing technology. The company's core innovation, Duplex Sequencing, enhances sequencing accuracy by over 10,000 times, enabling the detection of previously invisible mutations. This breakthrough technology has wide-ranging applications, including oncology, infectious disease diagnosis, organ transplant monitoring, genetic health, and forensics.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

miRecule, Inc. is a biotechnology company focused on developing innovative therapies for cancer and muscular dystrophy through its proprietary microRNA-based drug discovery platform, DREAmiR. Founded in 2016 and based in Gaithersburg, Maryland, the company leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. This platform integrates genomic sequencing, expression, and prognostic data to identify candidates for microRNA replacement therapy, enabling the creation of tailored RNA therapeutics that can directly target and rectify these genetic issues. miRecule's research is aimed at developing first-in-class therapies, with current lead programs addressing Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy. Through its advanced approach, miRecule aims to provide solutions that help patients overcome the debilitating effects of their conditions.

Verseau Therapeutics, Inc. is a biotechnology company focused on developing macrophage checkpoint modulators to address cancer, immune, and inflammatory diseases. Established in 2017 and headquartered in Lexington, Massachusetts, the company aims to create a new class of therapeutics that can modulate macrophage behavior. By identifying novel targets, Verseau's therapies are designed to facilitate a shift in macrophages from immune suppressors to activators, enhancing the effectiveness of immunotherapy for patients. Through this innovative approach, Verseau Therapeutics seeks to improve treatment outcomes for individuals suffering from various diseases.

Variant Bio Inc. is a biotechnology company focused on developing therapeutics through the exploration of human genetic diversity. Founded in 2018 and headquartered in Seattle, Washington, the company seeks to identify individuals and populations exhibiting extreme outlier traits relevant to various medical conditions. By employing advanced sequencing technologies, statistical genetics, and machine learning, Variant Bio analyzes the genetic underpinnings of these traits to uncover new therapeutic targets. The company's mission is to enhance global health by addressing unmet medical needs, particularly in areas such as neurodegenerative, autoimmune, and cardiometabolic diseases.

Adaptive Phage Therapeutics, Inc. is a clinical-stage company focused on addressing the global challenge posed by multi-drug resistant (MDR) pathogenic bacteria. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company offers therapeutic solutions utilizing its PhageBank, a comprehensive collection of bacteriophages—viruses that specifically target harmful bacteria. Through an advanced system for matching these phages to the unique bacterial infections of patients, Adaptive Phage Therapeutics aims to enable medical researchers to create effective treatments that can detect and combat MDR infections.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, aimed at creating DNA-based products across various industries. Founded in 2013, the company has developed a proprietary method that allows for the reliable, affordable, and sustainable production of long, high-quality, sequence-specific DNA. This innovative technology is designed to support advancements in industrial synthetic biology, personalized therapeutics, precision diagnostics, and has potential applications in information storage and nanotechnology. With a strong executive and scientific team, as well as a robust intellectual property portfolio, Molecular Assemblies is positioned to enhance the capabilities of researchers and contribute to the evolution of DNA-based applications.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

X-Vax Technology is a biotechnology company established in 2015 and headquartered in Jupiter, Florida. Its primary focus is the preclinical and clinical development of vaccines targeting mucosal infections caused by pathogens, including herpes, influenza, tuberculosis, and HIV, which affect millions globally. X-Vax is known for its development of a herpes vaccine candidate based on a genetically altered HSV-2 virus, specifically designed to elicit a robust immune response by inducing antibodies that lead to the killing of infected cells. This innovative approach utilizes Fc receptor activating antibodies that facilitate antibody-dependent cell-mediated killing, aiming to provide effective protection against herpes types 1 and 2. Through its pioneering research, X-Vax intends to advance the field of vaccines and enhance immune responses against significant viral infections.

Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. Utilizing its proprietary platform, the company identifies genomic sequences that regulate gene expression, facilitating advancements in viral gene therapy. Encoded Therapeutics has a diverse therapy pipeline targeting various genetic and acquired disorders across multiple disease pathways, including neurocircuitry, metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, the company is dedicated to improving patient outcomes through innovative gene therapy solutions.

Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Gencove is a software platform that specializes in high-throughput, cost-effective genome sequencing, utilizing low-pass sequencing technology. The company focuses on developing molecular and computational tools aimed at making whole-genome sequencing fast, affordable, and actionable. By setting a new standard in genomics research and diagnostics, Gencove caters to a wide range of industries, including agriculture and pharmaceuticals, thereby providing researchers with accessible genomic data.

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

GreenLight Biosciences, Inc. is a biotechnology company headquartered in Medford, Massachusetts, with an additional location in North Carolina. Founded in 2008, the company specializes in developing RNA-based solutions for agricultural and pharmaceutical purposes. It offers a proprietary technology platform that enables the efficient and cost-effective production of high-quality RNA, facilitating advancements in vaccine development, pandemic response, crop management, and the protection of pollinators. GreenLight develops mRNA-based vaccine candidates, including those aimed at preventing SARS-CoV-2 infections, and engages in collaborative efforts with industry leaders to further enhance its offerings. Through its innovative approach, GreenLight aims to contribute significantly to sustainable global development and food security.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

Tiburio Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, specializes in developing and manufacturing medicines for rare endocrine diseases and tumors related to the endocrine system. The company's primary focus is on TBR-760, a drug candidate designed to treat non-functioning pituitary adenoma (NFPA) using a dopamine-somatostatin chimeric molecule aimed at shrinking or halting tumor growth. Additionally, Tiburio explores other compounds like TBR-065 for treating rare endocrine diseases where effective treatments are limited.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Ribometrix, Inc. is a biotechnology company founded in 2014 and headquartered in Durham, North Carolina. The company specializes in discovering and developing small molecule drugs that target functional three-dimensional RNA structures, aiming to address various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools, including artificial intelligence and machine learning, to identify novel small molecules that can inhibit the production of disease-associated proteins. By focusing on RNA biology, Ribometrix seeks to lead a new paradigm in small molecule therapeutics, enhancing the understanding and modulation of RNA's role in disease mechanisms.

ENB Therapeutics, Inc. is a biopharmaceutical company based in New York, New York, that specializes in developing small molecule inhibitors aimed at treating melanoma and other cancers. Founded in 2015, the company focuses on overcoming drug resistance, a significant issue affecting over 50% of cancer patients. Its lead product, ENB-001, is a first-in-class selective endothelin B receptor (ETBR) inhibitor that has demonstrated the ability to significantly reduce tumor growth and enhance survival in preclinical studies. ENB-001 works by restoring T-cell infiltration into tumors, inhibiting metastasis, and improving the efficacy of immunotherapy. The product has received Orphan Drug Designation from the FDA, granting it market exclusivity and a robust intellectual property position. ENB Therapeutics is also developing a companion diagnostic to identify patients who could benefit from ENB-001, thus broadening its potential applications within the multi-billion-dollar immunotherapy market. The company's innovative approach aims to set a new standard of care by combining its therapies with existing immuno-oncology treatments to combat drug resistance and stimulate immune responses against cancer.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.